Nicholas Piramal Buys Two Brand Groups From India’s Khandelwal
This article was originally published in PharmAsia News
Khandelwal Laboratories has agreed to sell two of its brand divisions to Nicholas Piramal in an all-India deal. The deal for Anatortan and CEFI brand groups includes use of certain patents and a non-competing agreement by Nicholas Piramal for a pair of key Khandelwal drugs. The purchase of Anatortan and CEFI was put at $29 million. Nicholas Piramal expects to take advantage of its national sales and distribution network to market the formerly Khandelwal brands. (Click here for more
You may also be interested in...
TransEnterix hires Shameze Rampertab as its new CFO and said it expects “modest growth” in Q3 and Q4.
Keeping Track: Viltepso Earns Priority Review Voucher; Manufacturing Trips Fennec; Eagle Drops Ryanodex Exertional Heat Stroke Bid
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
CureVac raised hundreds of millions of dollars this year before its $213m initial public offering as its mRNA vaccine technology moved into the COVID-19 spotlight. Its stock price tripled on its debut.